SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - FRA:1SXP - DE000A3ENQ51 - Common Stock
19.48 EUR
+0.08 (+0.41%)
1SXP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 20 industry peers in the Life Sciences Tools & Services industry. 1SXP scores excellent on profitability, but there are some minor concerns on its financial health. 1SXP has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
In the past year 1SXP had a positive cash flow from operations.
Each year in the past 5 years 1SXP has been profitable.
Each year in the past 5 years 1SXP had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 9.61%, 1SXP belongs to the top of the industry, outperforming 95.00% of the companies in the same industry.
1SXP has a Return On Equity of 17.01%. This is amongst the best in the industry. 1SXP outperforms 90.00% of its industry peers.
1SXP's Return On Invested Capital of 13.93% is amongst the best of the industry. 1SXP outperforms 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1SXP is significantly above the industry average of 7.43%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.01% | ||
| ROIC | 13.93% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
The Profit Margin of 1SXP (15.05%) is better than 85.00% of its industry peers.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
1SXP's Operating Margin of 19.47% is fine compared to the rest of the industry. 1SXP outperforms 80.00% of its industry peers.
1SXP's Operating Margin has improved in the last couple of years.
1SXP's Gross Margin of 33.73% is on the low side compared to the rest of the industry. 1SXP is outperformed by 65.00% of its industry peers.
In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.47% | ||
| PM (TTM) | 15.05% | ||
| GM | 33.73% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1SXP is creating value.
1SXP has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, 1SXP has a worse debt to assets ratio.
2.2 Solvency
1SXP has a debt to FCF ratio of 1.74. This is a very positive value and a sign of high solvency as it would only need 1.74 years to pay back of all of its debts.
The Debt to FCF ratio of 1SXP (1.74) is better than 100.00% of its industry peers.
1SXP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.09, 1SXP belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.74 | ||
| Altman-Z | N/A |
ROIC/WACC1.74
WACC8.01%
2.3 Liquidity
A Current Ratio of 1.57 indicates that 1SXP should not have too much problems paying its short term obligations.
1SXP has a better Current ratio (1.57) than 65.00% of its industry peers.
1SXP has a Quick Ratio of 1.17. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.17, 1SXP is in line with its industry, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.00%.
Measured over the past years, 1SXP shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.04% on average per year.
Looking at the last year, 1SXP shows a small growth in Revenue. The Revenue has grown by 2.86% in the last year.
The Revenue has been growing by 13.84% on average over the past years. This is quite good.
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
3.2 Future
Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.71% on average per year.
1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.72% yearly.
EPS Next Y4.98%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
EPS Next 5Y10.71%
Revenue Next Year2.61%
Revenue Next 2Y5.89%
Revenue Next 3Y7.4%
Revenue Next 5Y7.72%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
1SXP is valuated rather expensively with a Price/Earnings ratio of 20.08.
Based on the Price/Earnings ratio, 1SXP is valued a bit cheaper than the industry average as 65.00% of the companies are valued more expensively.
1SXP is valuated rather cheaply when we compare the Price/Earnings ratio to 26.19, which is the current average of the S&P500 Index.
1SXP is valuated correctly with a Price/Forward Earnings ratio of 16.09.
1SXP's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. 1SXP is cheaper than 75.00% of the companies in the same industry.
1SXP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.50.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.08 | ||
| Fwd PE | 16.09 |
4.2 Price Multiples
1SXP's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. 1SXP is cheaper than 80.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than 65.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.18 | ||
| EV/EBITDA | 11.13 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as 1SXP's earnings are expected to grow with 12.50% in the coming years.
PEG (NY)4.03
PEG (5Y)N/A
EPS Next 2Y10.58%
EPS Next 3Y12.5%
5. Dividend
5.1 Amount
1SXP has a yearly dividend return of 0.79%, which is pretty low.
Compared to an average industry Dividend Yield of 0.69, 1SXP pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.33, 1SXP's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.79% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
1SXP pays out 16.41% of its income as dividend. This is a sustainable payout ratio.
DP16.41%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
FRA:1SXP (10/31/2025, 4:49:00 PM)
19.48
+0.08 (+0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.93B
Revenue(TTM)975.68M
Net Income(TTM)146.87M
Analysts78.95
Price Target30.13 (54.67%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.79% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.41%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.79%
PT rev (3m)-1.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.9%
EPS NY rev (1m)0%
EPS NY rev (3m)0.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.5%
Revenue NY rev (1m)-0.59%
Revenue NY rev (3m)-2.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.08 | ||
| Fwd PE | 16.09 | ||
| P/S | 3.01 | ||
| P/FCF | 59.18 | ||
| P/OCF | 14.41 | ||
| P/B | 3.4 | ||
| P/tB | 3.52 | ||
| EV/EBITDA | 11.13 |
EPS(TTM)0.97
EY4.98%
EPS(NY)1.21
Fwd EY6.21%
FCF(TTM)0.33
FCFY1.69%
OCF(TTM)1.35
OCFY6.94%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)4.03
PEG (5Y)N/A
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.01% | ||
| ROCE | 17.04% | ||
| ROIC | 13.93% | ||
| ROICexc | 14.46% | ||
| ROICexgc | 14.87% | ||
| OM | 19.47% | ||
| PM (TTM) | 15.05% | ||
| GM | 33.73% | ||
| FCFM | 5.08% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexgc growth 3Y-8.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.74 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 204.37% | ||
| Cap/Sales | 15.78% | ||
| Interest Coverage | 12.16 | ||
| Cash Conversion | 76.71% | ||
| Profit Quality | 33.75% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | N/A |
F-Score5
WACC8.01%
ROIC/WACC1.74
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
EPS Next Y4.98%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
EPS Next 5Y10.71%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
Revenue Next Year2.61%
Revenue Next 2Y5.89%
Revenue Next 3Y7.4%
Revenue Next 5Y7.72%
EBIT growth 1Y12.19%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year46.93%
EBIT Next 3Y24.15%
EBIT Next 5Y18.33%
FCF growth 1Y-28.77%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y-5.41%
OCF growth 3Y19.45%
OCF growth 5YN/A
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 5 / 10 to 1SXP.DE.
What is the valuation status of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for 1SXP stock?
The Price/Earnings (PE) ratio for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 20.08 and the Price/Book (PB) ratio is 3.4.
Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?
The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 3 / 10 and the dividend payout ratio is 16.41%.